Safety and Efficacy of ALLO-605 an Anti-BCMA Allogeneic CAR T Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma

Launched by ALLOGENE THERAPEUTICS · Aug 4, 2021

Keywords

ClinConnect Summary

No description provided

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Documented diagnosis of relapsed/refractory multiple myeloma (MM)
• • Subjects must have measurable disease
• • Subjects must have received ≥3 prior MM lines of therapy
• • Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
• • Adequate hematologic, renal, liver, pulmonary, and cardiac functions
• • Life expectancy of at least 3 months without treatment
• Exclusion Criteria:
• • Subjects with known active or history of central nervous system (CNS) or leptomeningeal involvement of myeloma or plasma cell leukemia
• • Current or history of thyroid disorder (including hyperthyroidism), except for subjects with hypothyroidism controlled on a stable dose of hormone replacement therapy
• • Autologous stem cell transplantation within last 6 weeks prior to the start of lymphodepletion
• • Any prior allogeneic hematopoietic stem cell transplantation
• • Systemic anti-cancer therapy within 2 weeks prior to the start of lymphodepletion